<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367730</url>
  </required_header>
  <id_info>
    <org_study_id>Majumdar #39637</org_study_id>
    <nct_id>NCT01367730</nct_id>
  </id_info>
  <brief_title>Assessment of Bone Micro-Architecture Using HR-pQCT</brief_title>
  <official_title>Non-Invasive Assessment of Bone Micro-architecture and Strength Changes in Men With Osteopenia and Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the context of male osteoporosis, we hypothesize that regional changes in trabecular bone,&#xD;
      as well as changes in cortical porosity will play a major role, and thus also affect bone&#xD;
      strength. In developing therapeutics the response of individual compartments, regional&#xD;
      variations post-therapy will have considerable impact on selecting the therapies as well as&#xD;
      monitoring response to therapy. This study, a precursor to other therapeutic trials, will lay&#xD;
      the ground-work for the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will recruit 80 subjects who will be stratified into groups based on their T-scores. All&#xD;
      subjects will be imaged at Baseline and 12 months. Measures of bone micro-architecture in the&#xD;
      tibia and radius using peripheral computed tomography, bone strength measures through finite&#xD;
      element analysis will be obtained at all time points. DXA measures at the spine, femur and&#xD;
      forearm will be obtained as reference measures. In addition whole body DXA scans will be&#xD;
      performed for assessment of body composition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure cross-sectional and longitudinal differences in bone micro-architecture and strength changes in men with BMD T-scores ≤-2.0 and those with T-scores &gt;-1.0.</measure>
    <time_frame>12 months</time_frame>
    <description>Trabecular bone micro-architecture as measured by trabecular number, trabecular BMD, and trabecular bone volume fraction (BV/TV). Cortical bone micro-architecture will be assessed by measuring cortical density &amp; thickness and porosity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Compressive biomechanical bone properties from Baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Calculate the change in compressive biomechanical properties using µ-finite element analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between BMD, bone micro-architecture, compressive biomechanical properties and body composition at all timepoints</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Association between BMD, bone micro-architecture, compressive biomechanical properties and body composition at all timepoints using DXA, HR-pQCT, microfinite element analysis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>osteoporosis and osteopenia</arm_group_label>
    <description>Subjects will be stratified based on DXA BMD T-scores.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community UCSF VA Medical Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men 50-85 years old&#xD;
&#xD;
          2. Patients must be willing to undergo a DXA scan.&#xD;
&#xD;
          3. Patients should be willing to undergo HRpQCT scan of the radius and tibia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to tolerate CT scans&#xD;
&#xD;
          2. Use of medications known to impact bone and mineral metabolism:&#xD;
&#xD;
               -  use of a bisphosphonate or teriparatide in the last year or for &gt;12 months ever;&#xD;
&#xD;
               -  current calcitonin;&#xD;
&#xD;
               -  prednisone &gt;5 mg daily or the equivalent glucocorticoid for &gt;10 days in the last&#xD;
                  3 months;&#xD;
&#xD;
               -  current testosterone therapy;&#xD;
&#xD;
               -  current thiazolidinedione (TZD);&#xD;
&#xD;
               -  current androgen deprivation therapy;&#xD;
&#xD;
               -  current use of an antiepileptic agent that alters hepatic vitamin D clearance;&#xD;
&#xD;
               -  use of thyroid hormone replacement with current thyroid stimulating hormone &lt;0.1&#xD;
                  mIU/L&#xD;
&#xD;
          3. Disease known to affect bone (e.g., primary hyperparathyroidism, Pagets disease,&#xD;
             clinically significant liver disease)&#xD;
&#xD;
          4. Illicit drug use or alcohol use &gt;3 drinks/day&#xD;
&#xD;
          5. Serum calcium &gt;10.2 mg/dL or calculated creatinine clearance &lt;30 mL/min&#xD;
&#xD;
          6. Weight &gt;350 pounds (the maximum weight limit of the DXA)&#xD;
&#xD;
          7. Hardware in the lumbar spine&#xD;
&#xD;
          8. History of bilateral hip replacement, or bilateral wrist or ankle fracture&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharmila Majumdar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Imaging Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteopenia and osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

